Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 8;123(Suppl 1):18–27. doi: 10.1038/s41416-020-01071-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Shown are forest plots for subgroup analyses of prognostic and additional factors for updated 3-year OS by pre-specified and post hoc exploratory subgroups in the ITT population. OS was defined according to the RECIST v1.1, and assessed by blinded-independent central review. The intention-to-treat population included all patients who underwent randomisation. Data cut-off for 3-year OS was January 31, 2019, and median follow-up was 33.3 months. Hazard ratio and 95% confidence intervals were not calculated if the subgroup had <20 events. CT chemotherapy, HR hazard ratio, NA not available, NR not reached, OS overall survival, PFS progression-free survival. Adapted from Gray et al.³⁴ Copyright (2019), with permission from Elsevier.